Abstract
Parkinsonian-like state was generated in mice by the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) to study the effects of Atremorine in Parkinson’s disease (PD) related neuropathology and behavior deficits. This devastating disease is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. Numerous therapeutic strategies have been developed to protect neuronal damage, although no effective treatment for PD has been validated yet. This study tested the preventive and therapeutic neuroprotective effect of Atremorine on MPTP parkinsonian mouse model. In addition to behavioral analysis, nigrostriatal dopaminergic neurons and inflammation biomarkers were directly quantified in the affected brain regions by specific antibody-antigen-binding methods. The affected neuronal populations and behavioural alterations induced by MPTP were significantly impaired in mice when treated with Atremorine-rich diet. Differences in the Atremorine content in diet induced some degrees of neuropathological and behavior therapeutical improvement, based on the progressive beneficial effects observed in nigro-striatal dopaminergic neurons of MPTPinduced mice. Data demonstrated that Atremorine promotes neuroprotection and behavior recovery in the injured MTPT-mouse brain by modulating the expression levels of tyrosine hydroxylase, glial proteins, apoptosis and endogenous dopamine and neuromelanin concentrations, probably the key to recover the basal ganglia function.
Keywords: Parkinson's disease, MPTP, neuroinflammation, neuroprotection, biotherapy, inflammation biomarkers.
Current Pharmaceutical Design
Title:Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease
Volume: 23 Issue: 18
Author(s): Ivan Carrera*, Lucia Fernandez-Novoa, Carolina Sampedro and Ramon Cacabelos
Affiliation:
- Health Biotechnology, EuroEspes Biotechnology, 15165 – Corunna,Spain
Keywords: Parkinson's disease, MPTP, neuroinflammation, neuroprotection, biotherapy, inflammation biomarkers.
Abstract: Parkinsonian-like state was generated in mice by the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) to study the effects of Atremorine in Parkinson’s disease (PD) related neuropathology and behavior deficits. This devastating disease is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. Numerous therapeutic strategies have been developed to protect neuronal damage, although no effective treatment for PD has been validated yet. This study tested the preventive and therapeutic neuroprotective effect of Atremorine on MPTP parkinsonian mouse model. In addition to behavioral analysis, nigrostriatal dopaminergic neurons and inflammation biomarkers were directly quantified in the affected brain regions by specific antibody-antigen-binding methods. The affected neuronal populations and behavioural alterations induced by MPTP were significantly impaired in mice when treated with Atremorine-rich diet. Differences in the Atremorine content in diet induced some degrees of neuropathological and behavior therapeutical improvement, based on the progressive beneficial effects observed in nigro-striatal dopaminergic neurons of MPTPinduced mice. Data demonstrated that Atremorine promotes neuroprotection and behavior recovery in the injured MTPT-mouse brain by modulating the expression levels of tyrosine hydroxylase, glial proteins, apoptosis and endogenous dopamine and neuromelanin concentrations, probably the key to recover the basal ganglia function.
Export Options
About this article
Cite this article as:
Carrera Ivan*, Fernandez-Novoa Lucia, Sampedro Carolina and Cacabelos Ramon, Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170210143530
DOI https://dx.doi.org/10.2174/1381612823666170210143530 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry Interventional Radiology in Paediatrics
Current Pediatric Reviews Bioinformatic Approaches Used in Modelling Human Tremor
Current Bioinformatics The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Recent Advances in Delivery Through the Blood-Brain Barrier
Current Topics in Medicinal Chemistry Direct Colorimetric Biosensors from Polydiacetylenes
Current Organic Chemistry Therapeutic Use of Chemokines
Current Pharmaceutical Design Gels and Jellies as a Dosage Form for Dysphagia Patients: A Review
Current Drug Therapy Applications of Molecularly Imprinted Polymers for Isolation of Estrogens from Environmental Water Samples
Current Analytical Chemistry Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Ganglioside GD3 as a Raft Component in Cell Death Regulation
Anti-Cancer Agents in Medicinal Chemistry Phosphorylation-Dephosphorylation Imbalance of Cytoskeletal Associated Proteins in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) FtsZ: A Novel Target for Tuberculosis Drug Discovery
Current Topics in Medicinal Chemistry Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism
Current Pharmaceutical Design An Overview of Pathogenesis and Pathophysiology in Endometriosis
Current Women`s Health Reviews Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Active Form of Neuroprotective Humanin, HN, and Inactive Analog, S7AHN, are Monomeric and Disordered in Aqueous Phosphate Solution at pH 6.0; No Correlation of Solution Structure with Activity
Protein & Peptide Letters Combating Mosquito-Borne Lymphatic Filariasis with Genomics Technologies: Enabling Novel Drug Discovery for Neglected Tropical Diseases
Current Pharmacogenomics and Personalized Medicine Current Psychopharmacology of Obsessive-Compulsive Spectrum Disorders
Current Neuropharmacology Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews